- Home
- HUMA vs NRXP Comparison
HUMA vs NRXP Comparison
Compare HUMA & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HUMA | NRXP |
|---|---|---|
| Founded | 2004 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 191.4M | 153.2M |
| IPO Year | 2020 | 2017 |
Fundamental Metrics
Financial Performance| Metric | HUMA | NRXP |
|---|---|---|
| Price | $0.65 | $3.55 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 4 |
| Target Price | $6.19 | ★ $38.25 |
| AVG Volume (30 Days) | ★ 8.4M | 1.1M |
| Earning Date | 05-15-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 79.37 | 69.70 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,038,000.00 | $1,225,000.00 |
| Revenue This Year | $444.16 | $2,547.84 |
| Revenue Next Year | $248.39 | $1,591.73 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.53 | $1.65 |
| 52 Week High | $2.55 | $5.06 |
Technical Indicators
Market Signals| Indicator | HUMA | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 49.47 | 52.66 |
| Support Level | $0.63 | $3.45 |
| Resistance Level | $0.75 | $3.67 |
| Average True Range (ATR) | 0.06 | 0.25 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 64.88 | 88.33 |
Price Performance
Historical ComparisonAbout HUMA Humacyte Inc.
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.